Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $855.00 Price Target at Morgan Stanley

Key Points

• Morgan Stanley raised Regeneron’s price target to $855 from $779 but maintained an “equal weight” rating, implying roughly 11.5% downside from the stock’s recent $966.44 price.
• Analyst sentiment remains broadly positive, with Regeneron carrying a “Moderate Buy” consensus rating and an average target of $893.59, although several targets remain below the current share price.
• Regeneron reported stronger-than-expected quarterly results, including $20.07 in EPS versus $16.51 expected and $5.12 billion in revenue, up 36.3% year over year. Shares traded near a one-year high following the results.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price boosted by equities researchers at Morgan Stanley from $779.00 to $855.00 in a research report issued to clients and investors on Monday, Benzinga reports. The brokerage currently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective suggests a potential downside of 11.53% from the stock's current price.

A number of other brokerages have also recently commented on REGN. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Royal Bank Of Canada lifted their price target on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a "sector perform" rating in a research note on Monday. Truist Financial upped their price objective on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the stock a "buy" rating in a research note on Monday. Evercore upped their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group lifted their target price on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a "buy" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $893.59.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $38.55 during trading hours on Monday, reaching $966.44. 881,733 shares of the stock traded hands, compared to its average volume of 822,683. The company has a 50 day moving average price of $793.30 and a 200 day moving average price of $738.05. The firm has a market capitalization of $99.50 billion, a price-to-earnings ratio of 21.35, a P/E/G ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a one year low of $591.52 and a one year high of $974.00. The company has a quick ratio of 3.66, a current ratio of 4.06 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to analysts' expectations of $4.58 billion. During the same quarter in the prior year, the business earned $11.83 EPS. The business's quarterly revenue was up 36.3% on a year-over-year basis. On average, equities research analysts expect that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. State Street Corp boosted its stake in Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company's stock valued at $3,014,621,000 after buying an additional 170,210 shares during the last quarter. Bank of America Corp DE grew its holdings in Regeneron Pharmaceuticals by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company's stock valued at $805,023,000 after buying an additional 101,469 shares in the last quarter. Amundi grew its holdings in Regeneron Pharmaceuticals by 0.4% during the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company's stock valued at $631,983,000 after buying an additional 3,742 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $473,872,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts broadly raised their forecasts following the upbeat quarter. Guggenheim increased its target to $1,100 with a “buy” rating, JPMorgan raised its target to $1,050 and assigned an “overweight” rating, and Bank of America lifted its target to $1,030 while maintaining a “buy” rating. Other firms also raised targets, with some forecasts reportedly reaching as high as $1,175. Analysts Raise Their Forecasts on Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: The combination of 70% EPS growth, 36% revenue growth, continued Dupixent momentum, encouraging Libtayo data and an expanded BARDA Ebola-treatment supply agreement points to improving commercial execution and pipeline value. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Positive Sentiment: Recent earnings-driven buying pushed REGN to a new one-year high, signaling strong market momentum and improved sentiment around the company’s growth outlook. Regeneron Hits 52-Week High After Standout Q3
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3 to shareholders of record November 20. The annualized yield is approximately 0.4%, providing modest shareholder income.
• Negative Sentiment: Several updated targets remain below the current trading level: RBC set $913 with a “sector perform” rating, Wells Fargo set $925 with “equal weight,” and Baird set $875 with “neutral.” These calls suggest some analysts view the recent rally as having limited near-term upside.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.